Nothing Special   »   [go: up one dir, main page]

AU2003275947A1 - Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator - Google Patents

Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator

Info

Publication number
AU2003275947A1
AU2003275947A1 AU2003275947A AU2003275947A AU2003275947A1 AU 2003275947 A1 AU2003275947 A1 AU 2003275947A1 AU 2003275947 A AU2003275947 A AU 2003275947A AU 2003275947 A AU2003275947 A AU 2003275947A AU 2003275947 A1 AU2003275947 A1 AU 2003275947A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
blood glucose
tissue factor
factor antagonist
glucose regulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003275947A
Inventor
Jakob Michael Back
Christian Meyer
Lars Christian Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003275947A1 publication Critical patent/AU2003275947A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003275947A 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator Abandoned AU2003275947A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201710 2002-11-06
DKPA200201710 2002-11-06
PCT/DK2003/000751 WO2004041302A1 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator

Publications (1)

Publication Number Publication Date
AU2003275947A1 true AU2003275947A1 (en) 2004-06-07

Family

ID=32309252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003275947A Abandoned AU2003275947A1 (en) 2002-11-06 2003-11-04 Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator

Country Status (2)

Country Link
AU (1) AU2003275947A1 (en)
WO (1) WO2004041302A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2008107362A2 (en) * 2007-03-07 2008-09-12 Novo Nordisk Health Care Ag Stabiliser and inhibitors of factor vii
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
PL2582728T3 (en) 2010-06-15 2018-01-31 Genmab As Human antibody drug conjugates against tissue factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699075B1 (en) * 1993-05-21 2001-12-12 Zymogenetics, Inc. MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition
CA2387857A1 (en) * 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003532691A (en) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ Severe illness neuropathy

Also Published As

Publication number Publication date
WO2004041302A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
AU2003234231A1 (en) New polyarylates for drug delivery and tissue engineering
AU2002252152A1 (en) Tissue electroperforation for enhanced drug delivery and sampling
AU2002319613A1 (en) Human tissue specific drug screening procedure
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
AU2003282961A1 (en) Patient activity monitor
AU2003253106A1 (en) Medical implant
AU2003232258A1 (en) Medical implant
AU2003241515A1 (en) Drug eluting implantable medical device
AU2003243150A1 (en) Resorption-controllable medical implants
AU2003217531A1 (en) Ocular drug delivery systems and use thereof
AU2003202603A1 (en) Compensation of human variability in pulse oximetry
AU2002232104A1 (en) Syringe for use in blood analysis
AU2003261346A1 (en) Medical examination table
AU2003282485A1 (en) Implantable tissue constriction device
AU2003214775A1 (en) Physiologically compatible cardiac assist device and method
AU2003234193A1 (en) Ultrasound methods and implantable medical devices using same
AU2003258298A1 (en) Medical implants
AU2002952993A0 (en) Therapeutic and diagnostic agents
AU2003289010A1 (en) Needle body for medical use and liquid-introducing tool
AU2003255645A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2002952927A0 (en) Combined wrist blood pressure and ecg monitor
AU2003235956A1 (en) Quinazoline derivative and medicine
AU2002950853A0 (en) Aminopyrimidine compound and pharmaceutical use thereof
AU2003248153A1 (en) Honey-based skin care preparation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase